Recruiting

Study on the Safety and Effectiveness of GTAEXS617 for Patients with Advanced Solid Tumors

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment called GTAEXS617 for patients with advanced solid tumors. Advanced solid tumors are a type of cancer that has spread and is not easily treated with surgery or radiation. The study aims to understand how safe the treatment is and how it behaves in the body, as well as its potential to fight cancer.

The study will be conducted in two main parts. In the first part, the treatment will be given alone to see how patients tolerate it and to determine the best dose. In the second part, the treatment will be combined with standard cancer treatments to see if it works better together. Throughout the study, researchers will monitor patients closely to ensure their safety and to gather information on how the treatment affects their cancer.

Participants in the study will take the treatment in the form of a tablet by mouth. The study will involve regular check-ups and tests to track the treatment's effects and any side effects. The goal is to find out if GTAEXS617 can be a safe and effective option for treating advanced solid tumors.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Joining the study
Upon joining the study, you will be asked to provide written consent, confirming your willingness to participate. This is a necessary step before any study-specific procedures begin.
Step 2
Initial assessment
An initial assessment will be conducted to confirm your eligibility. This includes checking your ability to swallow and retain oral medication, and ensuring you have adequate blood, liver, and kidney function.
Step 3
Treatment phase
You will begin taking the study medication, GTAEXS617, in the form of a tablet. This medication is taken orally. The dosage and frequency will be determined by the study team based on your specific needs and the study protocol.
The treatment phase is divided into different modules. In Module 1A, the focus is on understanding the safety of GTAEXS617 when used alone. In Module 1B, the medication is combined with standard care treatments to assess safety.
In Module 2A, the study evaluates the preliminary anti-tumor activity of GTAEXS617 alone, while Module 2B assesses its activity in combination with standard care.
Step 4
Monitoring and follow-up
Throughout the study, regular monitoring will occur to track your response to the medication and any side effects. This includes routine blood tests and other assessments as needed.
You will be asked to maintain a treatment diary to record your adherence to the medication schedule and any side effects you experience.
Step 5
End of study
The study is expected to conclude by November 11, 2027. At the end of the study, a final assessment will be conducted to evaluate your overall health and the effects of the treatment.

Who can join the trial?

11 criteria

Must be at least 18 years old.
Must be able and willing to provide written consent to participate in the study.
Must have an ECOG performance status of 0-1, which means you are fully active or have some symptoms but do not need bed rest during the day.
Must have an estimated life expectancy of more than 3 months.
Must be able to swallow and keep down oral medication.
Must have one of the following confirmed advanced solid tumors: head and neck cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), certain types of breast cancer, or ovarian cancer.
Must have a disease that is advanced, recurrent, or has spread to other parts of the body after standard treatments. If you have not received standard treatments, you may still be eligible if you cannot tolerate them or are not suitable for them.
Must have adequate blood, liver, and kidney function, as determined by specific medical tests.
If female, must not be pregnant or breastfeeding and must agree to use contraception if of childbearing potential.
If male, must agree to use contraception if having female partners who can become pregnant and must not donate sperm during the study and for at least 6 months after the last dose.
Must have tumor lesions or metastases that can be biopsied, as confirmed by a radiologist, except for bone metastases.

Who cannot join the trial?

3 criteria

Patients with **advanced solid tumors** cannot participate.
Patients who are not within the specified **age range** cannot participate.
Patients who are part of a **vulnerable population** cannot participate. This means groups that might need special protection or care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Centre hospitalier universitaire de Liege
Verified
Liege, Belgium
Cliniques Universitaires Saint-Luc
Responsive
Woluwe-Saint-Lambert, Belgium
Gasthuiszusters Antwerpen
Verified
Antwerp, Belgium

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

GTAEXS617 is a new medication being tested in this clinical trial. It is designed to help treat advanced solid tumors, which are a type of cancer. The trial is looking at how safe this medication is when used by itself and how well it works against tumors. Researchers are also studying how the body processes the medication and how patients respond to it. In some parts of the trial, GTAEXS617 is used alone, while in others, it is combined with standard treatments to see if it works better that way.

What is already known about the treatment

GTAEXS617 – GTAEXS617 is a medication currently being studied in clinical trials for its potential to treat advanced solid tumors. It is administered as a monotherapy or in combination with standard care regimens, although the specific form of administration is not detailed in the available data. The main focus of the trials is to assess its safety, how the body processes the drug, and its ability to fight tumors. At the molecular level, the exact mechanism of action is not specified, but it is being evaluated for its anti-tumor activity. GTAEXS617 is still in the experimental phase, and its classification in pharmacology is not yet fully established.

Investigated diseases

Advanced solid tumors – Advanced solid tumors refer to a group of cancers that form solid masses in various organs or tissues and have progressed to a more severe stage. These tumors can originate in different parts of the body, such as the lungs, breast, prostate, or colon. As they advance, they may grow larger, invade nearby tissues, and potentially spread to other parts of the body through the bloodstream or lymphatic system. The progression of these tumors can lead to increased symptoms, such as pain, swelling, or organ dysfunction, depending on their location. The growth and spread of these tumors can disrupt normal bodily functions and may require ongoing monitoring and management.